HOUSTON--(BUSINESS WIRE)--Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company specializing in the development and commercialization of early detection diagnostic tests for breast cancer and neurodegenerative diseases, today announced a new major international collaboration. Power3, in partnership with the Princess Haya Biotechnology Center and the Jordan University of Science and Technology will begin a clinical validation study for Power3’s BC-SeraPro™ Breast Cancer diagnostic blood test. The collaborative project will significantly expand Power3’s already-extensive breast cancer patient database and will further validate the pioneering work Power3 has already completed in the discovery of blood serum-based biomarkers of disease.
